PHATHOM PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $20.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $23.40M, a 89.04% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.12M.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $27.57M, a 38.26% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.11M, a 90.16% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $34.10M, a 2.38% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $34.94M, a 445.02% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $6.41M, a 26.14% decline from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $8.68M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $20.27M 10-Q · filed 2026-07-30 | $47.85M derived: sum of 3 quarters · filed 2026-07-30 | $48.96M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | -$3.12M 10-Q · filed 2026-04-30 | $24.45M derived: sum of 2 quarters · filed 2026-04-30 | $25.56M derived: sum of 3 quarters · filed 2026-04-30 | $37.94M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | $27.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.69M derived: sum of 2 quarters · filed 2026-02-26 | $41.06M derived: sum of 3 quarters · filed 2026-07-30 | $34.10M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $13.49M derived: sum of 2 quarters · filed 2026-07-30 | $6.53M 10-Q · filed 2025-10-30 | $26.47M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $12.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $5.42M 10-Q · filed 2026-07-30 | $25.36M derived: sum of 3 quarters · filed 2026-07-30 | $36.68M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | -$6.96M 10-Q · filed 2026-04-30 | $12.98M derived: sum of 2 quarters · filed 2026-04-30 | $24.30M derived: sum of 3 quarters · filed 2026-04-30 | $32.99M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $19.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.26M derived: sum of 2 quarters · filed 2026-02-26 | $39.95M derived: sum of 3 quarters · filed 2026-02-26 | $34.94M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $20.01M derived: sum of 2 quarters · filed 2025-10-30 | $14.99M 10-Q · filed 2025-10-30 | $25.26M derived: sum of 4 quarters · filed 2025-10-30 | ||
| 2024-06-30 | $8.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.67M 10-Q · filed 2025-08-07 | $13.94M derived: sum of 3 quarters · filed 2025-08-07 | $18.53M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$5.01M 10-Q · filed 2025-05-01 | $5.25M derived: sum of 2 quarters · filed 2025-05-01 | $9.84M derived: sum of 3 quarters · filed 2025-05-01 | $12.70M derived: sum of 4 quarters · filed 2025-05-01 | ||
| 2023-12-31 | $10.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $14.86M derived: sum of 2 quarters · filed 2025-03-06 | $17.71M derived: sum of 3 quarters · filed 2025-03-06 | $6.41M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $4.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.45M derived: sum of 2 quarters · filed 2024-11-07 | -$3.86M 10-Q · filed 2024-11-07 | $60.00K derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $2.86M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | -$8.45M 10-Q · filed 2024-08-08 | -$4.53M derived: sum of 3 quarters · filed 2024-08-08 | -$2.63M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$11.30M 10-Q/A · filed 2024-06-14 | -$7.39M derived: sum of 2 quarters · filed 2024-06-14 | -$5.49M derived: sum of 3 quarters · filed 2024-06-14 | $3.45M derived: sum of 4 quarters · filed 2024-06-14 | ||
| 2022-12-31 | $3.92M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $5.81M derived: sum of 2 quarters · filed 2024-06-14 | $14.75M derived: sum of 3 quarters · filed 2024-06-14 | $8.68M 10-K/A · filed 2024-06-14 | ||
| 2022-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $10.84M derived: sum of 2 quarters · filed 2023-11-09 | $4.76M 10-Q · filed 2023-11-09 | $4.60M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $8.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.87M 10-Q · filed 2023-08-10 | $2.70M derived: sum of 3 quarters · filed 2023-08-10 | $5.93M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$6.08M 10-Q · filed 2023-05-10 | -$6.07M 10-Q · filed 2022-05-10 | -$6.24M derived: sum of 2 quarters · filed 2023-05-10 | -$3.01M derived: sum of 3 quarters · filed 2023-05-10 | -$6.35M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$162.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $3.07M derived: sum of 2 quarters · filed 2023-02-28 | -$275.00K derived: sum of 3 quarters · filed 2023-02-28 | -$9.79M 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $3.23M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | -$113.00K derived: sum of 2 quarters · filed 2022-11-09 | -$9.63M 10-Q/A · filed 2022-11-09 | $6.72M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$12.86M 10-Q · filed 2022-08-02 | $3.49M derived: sum of 3 quarters · filed 2022-08-02 | $3.02M derived: sum of 4 quarters · filed 2022-08-02 | ||
| 2021-03-31 | -$9.52M 10-Q · filed 2022-05-10 | $6.83M derived: sum of 2 quarters · filed 2022-05-10 | $6.36M derived: sum of 3 quarters · filed 2022-05-10 | $13.00M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $16.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $15.88M derived: sum of 2 quarters · filed 2022-03-01 | $22.52M derived: sum of 3 quarters · filed 2022-03-01 | $24.01M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | -$468.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $6.17M derived: sum of 2 quarters · filed 2021-11-08 | $7.66M 10-Q · filed 2021-11-08 | $18.51M 10-Q · filed 2020-11-10 | $8.32M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | $6.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $8.13M 10-Q · filed 2021-08-10 | $8.79M derived: sum of 3 quarters · filed 2021-08-10 | $9.51M derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $1.49M 10-Q · filed 2021-05-11 | $2.15M derived: sum of 2 quarters · filed 2021-05-11 | $2.87M derived: sum of 3 quarters · filed 2021-05-11 | $3.22M derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $662.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $1.38M derived: sum of 2 quarters · filed 2021-03-30 | $1.73M derived: sum of 3 quarters · filed 2021-03-30 | $2.27M 10-K · filed 2021-03-30 | ||
| 2019-09-30 | $720.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.06M derived: sum of 2 quarters · filed 2020-11-10 | $1.60M 10-Q · filed 2020-11-10 | $1.74M derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $344.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $883.00K 10-Q · filed 2020-08-06 | $1.02M derived: sum of 3 quarters · filed 2020-08-06 | |||
| 2019-03-31 | $539.00K 10-Q · filed 2020-05-12 | $675.00K derived: sum of 2 quarters · filed 2020-05-12 | ||||
| 2018-12-31 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $225.00K 10-K · filed 2020-03-19 | ||||
| 2018-09-30 | $89.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |